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Abstract 
Background 
Pharmaceutical interventions for diabetes aim to control glycaemia and to prevent the 
development of complications, such as cardiovascular diseases. Some anti-hyperglycaemic 
drugs have been found to have adverse cardiovascular effects in their own right, limiting their 
therapeutic role. Glucokinase activity in the pancreas is critical in enhancing insulin release in 
response to hyperglycaemia. Glucokinase activators (GKAs) are novel agents for diabetes 
which act by enhancing the formation of glucose-6-phosphate leading to increased insulin 
production and subsequent suppression of blood glucose. Little, however, is known about the 
direct effects of GKAs on cardiovascular cells. 
Methods 
The effect of the GKAs RO28-1675 and Compound A on glucose utilisation in bovine aortic 
endothelial cells (BAEC) and rat MIN6 was observed by culturing the cells at high and low 
glucose concentration in the presence and absence of the GKAs and measuring glucose 
consumption. The effect of RO28-1675 at various concentrations on glucose-dependant 
signalling in BAEC was observed by measuring Smad2 phosphorylation by Western blotting. 
The effect of RO28-1675 on TGF-β stimulated proteoglycan synthesis was measured by 35S-
SO4 incorporation and assessment of proteoglycan size by SDS-PAGE. The effects of RO28-
1675 at on TGF-β mediated Smad2C phosphorylation in BAEC was observed by 
measurement of pSmad2C levels. The direct actions of RO28-1675 on vascular reactivity 
were observed by measuring arteriole tone and lumen diameter. 
Results 
GKAs were demonstrated to increase glucose utilisation in pancreatic but not endothelial 
cells. Glucose-activated Smad2 phosphorylation was decreased in a dose-dependent fashion 
in the presence of RO28-1675. No effect of RO28-1675 was observed on TGF-β stimulated 
proteoglycan production. RO28-1675 caused a modest dilation in arteriole but not contractile 
sensitivity. 
Conclusions 
GKA RO-28-1675 did not increase glucose consumption in endothelial cells indicating the 
absence of GK in those cells. No direct deleterious actions, in terms of atherogenic changes 
or excessive vasoactive effects were seen on cells or vessels of the cardiovascular system in 
response to GKAs. If reflected in vivo, these drugs are unlikely to have their use 
compromised by direct cardiovascular toxicity. 
Keywords 
Transforming growth factor beta, Smads, Diabetes, Pleiotropic actions 
Background 
There is an epidemic of Type 2 diabetes mostly driven by increasing worldwide obesity and 
sedentary life style factors [1, 2]. The defining metabolic parameters of Type 2 diabetes are 
insulin resistance and pancreatic beta cell failure and they are associated with increased rates 
of cardiovascular disease [3–5]. Existing drugs for the treatment of these factors have thus far 
been overwhelmed by the pervasive natural history of the disease and no treatment regimens 
are available which can maintain long term normoglycemia and prevent cardiovascular 
disease. 
The rapid increase in the occurrence of obesity-related Type 2 diabetes commenced in the 
early 1980s [6]. This event was not fully appreciated by the pharmaceutical industry which in 
the relevant period and area was concentrating on the development of anti-hypertensive 
agents; accordingly, there was a large gap in the discovery and introduction of new classes of 
drugs for the treatment of hyperglycemia. Intense research over the last several decades has 
partially redressed this situation and there are now many new and emerging classes of anti-
hyperglycemia agents including, incretin mimetics, dipeptidyl peptidase (DDP)-4 inhibitors, 
sodium glucose co-transport 2 inhibitors and in the current context, glucokinase activators 
(GKAs) [7–9]. Glucokinase activators (GKAs) are at different stages of clinical development 
[10]. GKAs have been under clinical development since 1990 and in this time over 100 patent 
applications for this class of compound have been filed, with several agents proceeding to 
short-term clinical trials in humans [11]. The large number of GKAs available and chemical 
diversity amongst these molecules makes generalisation and intra-class comparison difficult 
[12]. Broadly, the class shows high effectiveness at reducing fasting and basal glucose levels 
and improves glucose tolerance [11]. GKAs have effects at the liver which may be beneficial 
in reducing hepatic glucose output, but may have the unwanted effect of inducing 
hypertriglyceridemia and hepatic steatosis [12, 13]. Recent studies with a GKA have shown 
that in rats one analogue enhances beta cell function and suppresses hepatic glucose 
production, both essential elements of an anti-hyperglycaemic action [14]. The cardiovascular 
risk associated with these effects warrants investigation notwithstanding that it must be 
appreciated that there is currently no GKA in current clinical use. 
Hexokinases are enzymes that utilise phosphate from ATP to phosphorylate hexoses yielding 
phosphohexose and thus, catalysing the conversion of glucose to glucose-6-phosphate (G-6-
P). There are four mammalian HK isozymes - Type I, II, III and IV that are located in 
different tissues of the body and they differ in their physiological function [15]. HKI-III are 
100 kDa proteins with relatively high affinity for glucose and are inhibited by physiological 
concentrations of glucose-6-phosphate (G-6-P) [15, 16]. HKI and III have a catalytic active 
site at the carboxyl terminal region whereas HKII has a catalytic active site in both the amino 
(N) and the carboxyl (C) terminal [15]. HKI is found in high levels in the brain and skeletal 
muscle, HKII is found in insulin-sensitive tissues including skeletal muscle, adipose tissue 
and vascular smooth muscle cells and physiologically. 
HKIII is found in the kidney, lung, liver, spleen and brain [15]. In the family of hexokinases, 
glucokinase (GK), also known as hexokinase IV or D, has a lower affinity for glucose than 
other members of the hexokinase family; GK responds to and regulates glucose 
concentrations at higher glucose levels than the other isoforms. GK is less inhibited by its 
catalytic product, glucose-6-phosphate (G-6-P) than are the other members of the HK family. 
GK senses (blood) glucose in the physiological level and higher, hence pathophysiological 
range, and its action leads to the enhanced secretion of insulin from pancreatic beta cells. The 
expression of GK has not been thoroughly investigated and it is presently considered to have 
a narrow spectrum of tissue expression mostly in glucose sensing and sensitive tissues 
(pancreas and liver). 
Physiologically, increasing blood glucose levels, for example, post-prandially, leads to 
activation of GK, increased insulin secretion and a blood glucose lowering response [17]. 
With the knowledge that genetic mutations of GK had effects on glucose metabolism, the 
potential arose that GKs could be targeted therapeutically for the regulation of glucose 
metabolism and potentially for the treatment of the hyperglycaemia of diabetes [18]. Drug 
development in this area has yielded several structurally distinct classes of agents with 
differing effects and potencies [19, 20]. Of the family of HKs I – IV, GK is the only isoform 
with an “activator site” and thus the only HK which is theoretically mechanistically 
responsive to GKAs. GKAs target an allosteric site that is only exposed when glucose is 
bound to GK and GKAs interact with this site in a thermodynamically reversible manner. The 
binding of a GKA to the allosteric site of a glucose bound GK enzyme stabilizes the GK in an 
active conformation which activates the enzyme and also prevents its interaction with 
glucokinase regulatory protein (GKRP) and prevents nuclear sequestration. There is no 
published data showing GKAs effects on other HKs except for two references to unpublished 
data in papers from pharmaceutical company laboratories which state GKAs were specific for 
GK and do not activate HKI-III [21, 22]. The in vivo actions (hypoglycaemia) of most GKAs 
correlates closely with their in vitro efficacies which indicates that the proposed biochemical 
action, being activation of GK, is the actual mechanism of action mediating the 
hypoglycaemic effects in vivo[23]. There are also other drugs that may work at least partially 
via an action involving GKs – mitiglinide induces translocation of GK from the nucleus to 
the cytoplasm where it can mediate a hypoglycaemic effect [24, 25]. 
As the history of drug development in the area of diabetes and cardiovascular disease well 
reflects [26–28], efficacy is assessed as the effect on a risk factor but the ultimate target of a 
particular therapy, the effect on CVD, is often not considered. It is possible to hypothesize, 
that if glucose causes cardiovascular disease and GKAs stimulate the entry and utilization of 
glucose by cells of the vascular system, then GKAs might indeed have direct deleterious 
effects on the cardiovascular system. These effects might arise from either the presence of 
GKAs in cardiovascular cells or nominally off target effects of GKAs to activate GKs in 
vascular smooth muscle and endothelial cells. 
We have previously examined the effects of anti-diabetic agents on atheorgenic and fibrotic 
responses in vascular cells and multiple agents have diverse actions which contribute to our 
understanding of their actions [29]. We proposed a series of studies to investigate the 
mechanism of glucose utilisation in endothelial cells (ECs), the impact of GKAs on glucose 
metabolism and the vascular response to the anti-hyperglycemic action of GKAs, and studies 
examining the effect of GKAs on the development of atherosclerosis in our well established 
in vitro model. The overall aim was to develop a comprehensive knowledge of factors 
affecting glucose effects in vascular cells and to determine if GKAs have direct or indirect 
hypoglycaemic actions to modify the progression of atherosclerosis. We explored the 
physiological connection between the effects of glucose on cell metabolism, TGF-β 
signalling and several other vascular properties which would reflect upon the positive or 
negative impact of GKAs on elements of cardiovascular disease. We observed that GKAs did 
not increase glucose uptake in endothelial cells and did not have pleiotropic actions to 
enhance glucose mediated toxicity and we identified several favourable actions most likely 
unrelated to actions on GK. 
Materials and methods 
Materials 
Dulbecco’s Modified Eagle medium (DMEM) (0 mM and 25 mM glucose) was from GIBCO 
BRL, Grand Island, USA. SB431542 and DEAE-sephacel were purchased from Sigma-
Aldrich, MO, USA. GKA (RO28-1657) was from Axon Medchem, The Netherlands. Anti-
rabbit IgG HRP, GAPDH , anti-phospho-Smad2 (ser465/467) rabbit monoclonal antibody 
and human transforming growth factor beta-1 (TGF-β) was from Cell Signalling Technology, 
Danvers, USA. Glucokinase activator compound A was from Merck, Darmstadt, Germany. 
[
35
S]-Sulfate was from MP Biomedicals, Irvine, CA. Cetylpyidinium chloride (CPC) was 
from Uni-Lab Chemicals and Pharmaceuticals, India. 3MM Whatman chromatography paper 
was from Whatman International, Ltd., Maldstone, UK. YSI 2300 Stat plus glucose and 
lactate analyser kindly provided by Professor Stephen Bird, Exercise and Metabolism 
Research Laboratory, RMIT University. YSI buffer concentrated kit, YSI glucose standard 
were from YSI Inc, Yellow Spring, USA. 
Culture of bovine aortic endothelial cells and rat MIN6 pancreatic beta cells 
Primary cultured bovine aortic endothelial cells (BAEC) were prepared by collagenase 
treatments of the aortas acquired aseptically from the abattoirs [30]. The cells were passaged 
to provide sufficient cells for frozen stocks and experimentation. Stock cultures were thawed 
from the frozen stocks in liquid nitrogen and were maintained in Dulbecco’s Modified Eagle 
Medium (DMEM) 5 mM glucose, 10% foetal bovine serum (FBS) and 1% antibiotics 
(streptomycin and penicillin) and incubated in 5% CO2 at 37°C. 
MIN6 pancreatic beta cells were provided by Professor Jun-ichi Miyazaki, Osaka University 
Medical School Japan. The cells were maintained in high glucose 25 mM DMEM containing 
10% FBS (FBS heat inactivated for 30 min at 60°C) and 2.5 μl of 2-mercaptoethanol. 
Cell culture protocol for experimentation 
For experimentation, BAEC between passages 20–50 were subcultured in 60 mm diameter 
dishes and 24 well plates at a density of 200,000 and 50,000 cells/well until they were 
confluent cultures. Cells were serum deprived in DMEM, 5 mM glucose, 0% FBS for 24 h. 
For glucose utilisation experiments quiescent BAEC were treated with different glucose 
medium concentration 2.5, 5, 15, 25 mM containing 0% FBS in the presence and absence of 
glucokinase activator (GKA) RO28-1675 (10 μM) and with TGF-β (2 ng/mL) as positive 
control and medium was collect at different time points 0, 4, 8, 24 h. For phosphorylated 
Smad2C protein detection experiments, BAEC were treated with RO28-1675 (0.1, 0.3, 1, 3, 
10 μM) in the presence of high glucose (15 mM) for 1 h. For a time course BAEC were 
treated with 15 mM glucose medium at different time points 0, 15, 30, 60, 120, 240 min. For 
GKA dose response on phosphorylated Smad, BAEC were treated with different glucose 
medium concentrations 5, 10, 15, 20, 25 mM containing 0% FBS. For proteoglycan 
experiments cells were treated with GKA RO28-1675 (1, 3, 10 μM), SB431542 (3 μM) and 
GKA, compound A (1, 3, 10 μM) in presence of TGF-β (2 ng/ml) and then radiolabeled with 
[
35
S]-sulfate (50 μCi/ml) for 24 hours. 
MIN6 pancreatic beta cells were used as positive controls for glucose and GKA responses. 
These cells were subcultured between passages 30–45 in 24 well plates until they reached 
80% confluence. MIN6 cells were then washed twice with DMEM containing no glucose and 
glucose deprived for 24 hours in DMEM containing no glucose, 10% FBS and 2.5 μl of 2-
mercaptoethanol. Cells were then treated with either 5 or 25 mM glucose in the presence and 
the absence of two GKA compounds, RO28-1675 (10 μM) and Compound A (10 μM). 
Glucose utilisation studies 
To determine cellular glucose consumption, glucose concentrations in the medium were 
measured pre- and post-treatment using YSI Stat plus 2300 glucose and lactate analyser. 
Confluent cultures were treated as described, incubated at 37°C then the media (500 μl) from 
each well of each treatment was collected in 1 ml eppendorf tubes and centrifuged for 10 min 
at 5000 rpm. Glucose concentrations were measured by placing the eppendorf tube in the 
sipper tube of the YSI analyser; the sipper automatically aspirates 25 μl of the sample. 
Glucose concentration measurements were displayed on screen. The YSI system buffer in the 
instrument contained sodium dihydrogen phosphate (25 mM), sodium hydrogen phosphate 
(45 mM), and sodium chloride (31 mM) used to flush the sample chamber through the 
system. 
Western blotting 
Total cells lysed were resolved on 10% acrylamide gels by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). Protein was then transferred on a PVDF 
membrane in transfer buffer (3.7% SDS, 20% methanol, 48 mM Tris base, 39 mM Glycine) 
at 4°C. Membranes were blocked in 5% skim milk powder and then incubated with primary 
rabbit monoclonal antibodies (anti-phospho-Smad2C (Ser465/467) (1:1000), anti-Smad2 
(1:1000) and anti-GAPDH (1:4000)) followed by a secondary horseradish peroxidase-anti-
rabbit IgG (1:1000) and ECL detection. Blots were imaged using the Bio-Rad gel 
documentation system and densitometry analysis was performed on blots from at least three 
experiments with Quantity One imaging software. 
Quantitation of proteoglycans synthesis 
After cells were treated as mentioned in tissue culture for experimentation section, media 
from each of 24 wells containing secreted proteoglycans was collected and protease inhibitors 
(100 mM 6-amino caproic acid, 5 mM benzamidine hydrochloride) added. Radiolabel 
incorporation into proteoglycans were measured by cetylpyridium chloride (CPC) 
precipitation assay as previously described in detail [31]. 
Assessing proteoglycan size by SDS-PAGE 
Proteoglycans labelled with [
35
S]-sulphate were prepared for SDS-PAGE by isolation through 
the DEAE sephacel anionic exchange mini columns. Samples were added to pre-equilibrated 
columns and are then washed extensively with low salt buffer (8 M urea, 0.25 M NaCl, 2 mM 
disodium EDTA, 0.5% Triton X-100). Proteoglycans were eluted using high salt buffer (8 M 
urea, 3 M NaCl, 0.02 M EDTA, Triton-X). 
Equal counts of proteoglycans (20,000 - 50,000 cpm) were precipitated by ethanol solution 
(1.3% potassium acetate in 95% ethanol) chondroitin sulfate was added as a cold carrier. 
Samples were suspended in 20 μl of buffer (8 M urea, 2 mM disodium EDTA, at pH 7.5) and 
20 μl sample buffer (0.5 M Tris–HCl pH 6.8, 10% SDS, 50% glycerol, 2-mercaptoethanol, 
and 0.1% bromophenol blue). Proteoglycans were separated on gradient separating gel [32] 
with 4-13% acrylamide separating gels and 3% acrylamide stacking gels and run overnight at 
60 V. Methylated protein molecular weight marker (Rainbow™ [14C]) was used. Processed 
and dried gels were exposed to an imaging plate (Fujifilm BAS-MS 2040 imaging plate). For 
approximately 4 days. Images were developed on a phosphoimager (Fujix BAS 1000 image 
plate scanner) and viewed using imaging software (Fujifilm Multi-Gauge). 
Cannulated arteriole assessment of vascular reactivity 
All animal procedures were approved by the Animal Experimentation Ethics Committee of 
RMIT University. Adult Wistar rats (n = 6, 281 ± 13 g body weight) were killed by CO2 
asphyxiation and cervical dislocation and the cremaster muscles were surgically removed to 
ice cold Kreb’s solution. The primary arteriole was micro dissected, cannulated with glass 
pipettes, placed on the stage of an inverted microscope, pressurised at 70 mmHg (lumen 
pressure) and superfused with krebs/HEPES buffer at 34°C. Arterioles were equilibrated for 
60 min, until pressure-induced constriction (myogenic tone) developed, usually about 50% of 
the maximum diameter measured in calcium free Krebs (2 mM, EGTA) and the diameter 
(μm) was measured by video microscopy using either an automated computer program 
(DiamTrak) or video callipers as previously described [33]. Changes in diameter were 
measured in response to increasing concentrations of phenylephrine or acetylcholine (10nM 
to 10 μM Sigma, Australia) in the presence and absence of the glucokinase activator RO28-
1675 (10 μM). In addition changes in arteriole diameter were recorded in response to 
increasing concentrations of RO28-1675 or DMSO (vehicle). 
Data were collected using MacLab Chart (ADInstruments, v 4.2) and analysed using 
GraphPad Prism. Results are expressed as the mean ± SEM, n represents the number of 
arterioles and animals and ANOVA was used to determine the effect of RO28-1675 treatment 
relative to vehicle (DMSO). Arteriole diameter in the figures is expressed as percentage of 
the maximum diameter, measured in 0 mM calcium, 2 mM EGTA containing Kreb’s 
solution. 
Statistical analysis 
Data was normalised and shown as the mean ± standard error of the mean (SEM) of three 
independent experiments performed in triplicate, unless stated otherwise. Western blotting 
and proteoglycan experiments were analysed by a 1-way ANOVA and glucose utilisation 
experiments were analysed by 2-way ANOVA. Results were considered significant when the 
probability was less than 0.05 (*P ≤ 0.05), 0.01 (**P ≤ 0.01) and 0.001(***P ≤ 0.001) 
Results 
Glucokinase activators increase glucose metabolism in MIN6 pancreatic rat 
beta cells 
Two GKA compounds, (RO28-1675 and Compound A) were used to test their known action 
on rat MIN6 pancreatic beta cells expressing GK enzyme. Glucose levels in the medium were 
measured in the presence and absence of (RO28-1675 and Compound A). The direct measure 
of glucose concentration in the medium was used to determine glucose consumption. Glucose 
consumption was calculated by the difference of the basal, RO28-1675 and compound A after 
24 hour incubation under both normal (5 mM) and high (25 mM) glucose conditions. The 
data for the measurement of the glucose concentration in the media after 24 h inclusion is 
shown in Figure 1A upper panel. From this data we calculated the actual rate of glucose 
consumption (Figure 1B). RO28-1675 caused a 106% increase in the rate of glucose 
consumption/well/24 hour and Compound A caused 104% increase in rate of glucose 
consumption/well/24 hour in the 5 mM glucose treatment condition (Figure 1B). MIN6 beta 
cells exposed to 25 mM glucose showed a 286% increase in the rate of glucose consumption 
compared to 5 mM glucose treatment. Under the 25 mM glucose treatment conditions, both 
RO28-1675 and compound A at 10 μM caused 66.3% increase in the rate of glucose 
consumption/well/24 hour compared to basal (Figure 1B). The data showed that GKAs 
enhanced the metabolism of glucose in MIN6 pancreatic beta cells and validated the assay for 
demonstrating the effects of GKAs in cultured cells. 
Figure 1 Effect of GKA on glucose concentration(A) and consumption(B) on rat MIN6 
pancreatic beta cells. A. MIN6 cells treated with either 5 mM or 25 mM glucose medium 
conditions in the presence and absence of two glucokinase activators (RO28-1675 and 
Compound A) at 10 μM for 0–24 h. Direct D-glucose levels were measured in the medium 
for each treatment. Data presented from an experiment utilizing 3 wells/treatment. ##p < 0.01 
= basal (24 h) versus basal (0 h) and ##p < 0.01 = treatment versus basal (24 h) determined 
using one-way-ANOVA on a per well basis. B. RO28-1675 and Compound A increased (P < 
0.01) the rate of consumption of glucose by MIN6 cells treated with 5 mM and 25 mM 
glucose compared to basal levels of glucose consumption after 24 h. Results are **p < 
0.01treatment versus basal, determined using one-way-ANOVA. 
We then utilised the same assay to assess the effect of GKAs on glucose utilisation by BAEC. 
BAEC were exposed to different glucose medium concentrations (2.5, 5, 15, 25 mM) +/− 
GKA (RO28-167 10 μM). Incubation proceeded for different time points (0, 4, 8, 24 h) and 
glucose levels were measured for each treatment. TGF-β (2 ng/ml), which activates cellular 
metabolism and increases glucose consumption was used as a positive control for the 
physiological sensitivity of the assay [34–36]. In the BAEC, the rate of glucose consumption 
increased with the media glucose concentration reaching a maximum rate of consumption at 
approximately 30 mM. The rate of glucose consumption was increased in cells treated with 
TGF-β but was completely unaffected in cells treated with RO28-1675 at the same 
concentration (10 μM) which stimulated glucose consumption in the MIN6 pancreatic beta 
cells (Compare Figure 1B and Figure 2). The kinetic parameters for the curves are shown in 
Table 1. The maximum calculated rates of glucose metabolism were 0.14 ± 0.02 
mM/well/hour and 0.17 ± 0.02 mM/well/hour (n.s.) in the absence and presence of RO28-
1675, respectively and this was increased to 0.21 ± 0.01 mM/well/hour in the presence of 
TGF-β (Table 1). Half maximally effective concentrations of glucose were not appreciably 
different amongst the three treatment groups (Table 1). Thus, the GKA RO28-167 did not 
increase the consumption of glucose by BAECs implying that there is either no GK target or 
it is expressed at such a low level that its activation by GKAs does not alter glucose 
utilisation in BAEC. 
Figure 2 The relationship between the rate of glucose consumption and D-glucose 
concentration. Endothelial cells treated with 2.5, 5, 15, 25 mM D-glucose −/+GKA and 
TFG-β. Basal represent normal levels of the rate of glucose consumption mM/well/hour in 
endothelial cells. In the presence of GKA (10 μM) there was no effect on the rate of glucose 
consumption. Results are the mean ± SEM from 3 experiments in triplicate **p < 0.01 versus 
basal, ***p < 0.001 versus basal determined using two-way ANOVA. 
Table 1 Mean Vmax,Km and R
2
 for the rate of glucose consumption in bovine aortic 
endothelial cells 
 Basal GKA (RO28-1675) (10 μM) TGF-β (2 ng/ml) 
Vmax 0.14 ± 0.02 0.17 ± 0.02 0.21 ± 0.01 
Km 6.42 ± 1.97 9.08 ± 2.12 4.47 ± 0.83 
R
2
 0.83 0.92 0.91 
Results are mean ± SEM of three separate experiments. 
Glucose induced Smad2 activation in endothelial cells 
High glucose (HG) induces a rapid increase in TGF-β signalling in fibroblasts and epithelial 
cells [37]. This effect was tested in concentration response studies in vascular endothelial 
cells. Smad phosphorylation was assessed by Western blotting and the expression of Smad2 
and GAPDH were used as controls. BAEC incubated in glucose concentrations (5, 10, 15, 20, 
25 mM) for one hour demonstrated that 15 mM induced maximal stimulation of Smad2 
transcription factor phosphorylation at the carboxy terminal by 87% increase compared to 
basal 5 mM (Figure 3A and B). TGF-β (2 ng/ml) used as a positive control caused a 585% 
increase of Smad2C phosphorylation compared to basal 5 mM (Figure 3). We then evaluated 
the time dependency of the impact of glucose on pSmad2C levels. BAEC were treated with 
15 mM glucose at different time points 0, 15, 30, 60, 120, 240 min (Figure 4A and B). We 
observed a 94% increase of Smad2C phosphorylation at a peak of 60 min compared to basal 
levels of Smad phosphorylation at 0 min (Figure 4). TGF-β (2 ng/ml) used as positive 
control, increased Smad2C phosphorylation by 520% compared to basal levels of Smad 
phosphorylation. We observed that glucose had a parabolic response in inducing Smad2 
phosphorylation in BAEC which was both time and dose-dependent. The peak responses 
were observed at 15 mM glucose and 60 min stimulation so these conditions were used to 
study the effects of GKAs on Smad-dependent signalling in BAEC. 
Figure 3 Effect of D-glucose on the phosphorylation of Smad2C in endothelial cells. A. 
Western blot of whole cell lysates from BAECs treated with glucose (5–25 mM) for 60 min. 
TGF-β (2 ng/ml) for 5 min was used as positive control. Cell lysate were were resolved on 
SDS-PAGE and transferred onto a PVDF membrane. The membrane was probed with anti-
phospho-Smad (Ser465/467). Also probed with anti-Smad2 and anti-GAPDH. 
Chemiluminescence was used to detect the proteins of interest. B. Histogram is a 
densitometric quantitation of 3 Western blots. Results **p < 0.01 treatments versus basal (5 
mM) n = 3 experiments determined by one-way ANOVA. 
Figure 4 Effect Smad2C phosphorylation on endothelial cells treated with 15 mM D-
glucose for up to 4 h. A. Western blot of whole cell lysates from BAECs treated with 15 mM 
D-glucose for up to 240 min. Cells treated with TGF-β (2 ng/ml) (5 min) were used as 
positive control. Cell lysate were resolved on SDS-PAGE and transferred onto a PVDF 
membrane. The membrane was probed with anti-phospho-Smad(Ser465/467) antibody. Also 
probed with anti-Smad2 and anti-GAPDH . Chemiluminescence was used to detect the 
proteins of interst. B. Histogram is a denstitometric quantitation of 3 Western blots. Results 
determined by one-way ANOVA **p < 0.01 treatments versus basal n = 3 experiments. 
GKAs effects on glucose dependent signalling in endothelial cells 
We had reasoned that if GKAs increased the effect of glucose on cardiovascular cells, such as 
endothelial cells, then glucose dependent responses might be intensified. We demonstrated 
that glucose induces Smad2 carboxy terminal phosphorylation in BAEC indicating activation 
of the canonical TGF-β signalling pathway in these cells. Accordingly, we tested the effect of 
a GKA (RO28-1675) on glucose induced Smad2C phosphorylation in BAEC. Cells were 
treated with glucose (15 mM) +/− GKA (RO28-1675) at concentrations 0.1-10 μM for 60 
min and we assessed Smad2C phosphorylation by Western blotting (Figure 5A and B). 
Glucose (15 mM) increased basal levels of pSmad2C by 101% compared to low glucose 
(LG) 5 mM (Figure 5). GKA (RO28-1675) caused a concentration-dependent inhibition of 1-
10 μM in glucose mediated Smad2C phosphorylation (Figure 5). At the highest 
concentrations tested (3 μM and 10 μM) GKA restricted the response of HG (15 mM) to 
basal levels. The half maximally inhibitory concentration of RO28-1675 was approximately 1 
μM (Figure 5B). TGF-β (2 ng/ml) used as positive control caused 500% increase of Smad2C 
phosphorylation levels compared to basal (LG) (Figure 5). This data shows that GKA RO28-
1675 caused an inhibition of glucose-dependent pSmad2C signalling in BAECs. 
Figure 5 Effect of GKA on D-glucose mediated Smad2C phosphorylation in endothelial 
cells. A. Western blot of whole cell lysates from BAEC treated with D-glucose 15 mM in the 
presence and absence of GKA (RO28-1675) (0.1-10 μM). TGF-β was used as positive 
control. Cell lysate were resolved on SDS-PAGE and transferred onto a PVDF membrane. 
This membrane was probed with anti-phospho-Smad(Ser465/467). Also probed for anti-
Smad2 and anti-GAPDH. Chemiluminescence was used to detect proteins of interest. B. 
Histogram is a densitometric quantitation of 4 western blots. Results ##p < 0.01 = compared 
to untreated basal level (LG) **p < 0.01 compared to agonist treated (HG), n = 4 experiments 
statistical analysis determined by one-way ANOVA. 
Effects of GKAs on transforming growth factor beta (TGF-β) stimulated 
proteoglycan synthesis and specifically glycosaminoglycan elongation 
The synthesis of proteoglycans (biglycan) in association with increased GAG size is 
stimulated by the canonical TGF-β Smad/phosphorylation pathway in vascular smooth 
muscle cells and BAEC [38–40]. BAECs were treated with TGF-β (2 ng/ml) to determine the 
effect on proteoglycan synthesis in the presence and absence of GKA (RO28-1675, 1-10 
μM). TGF-β (2 ng/ml) increased 35S-SO4 incorporation into proteoglycans by 78.2% 
compared to basal (Figure 6). In the presence of GKA there was no effect on TGF-β mediated 
35
S-SO4 incorporation in BAEC. SB431542 (3 μM) is an inhibitor of the serine/threonine 
kinase activity of TGF-β receptor type 1 inhibitor (ALK V) directed at Smads [41]; as 
expected SB431542 (3 μM) almost completely blocked the stimulation by TGF-β (Figure 6). 
The assessment of proteoglycan size by SDS-PAGE indicated TGF-β (2 ng/ml) increased 
proteoglycan size and the GKA had no effect on TGF-β stimulated increase in the size of 
biglycan a response which occurs due to hyperelongation of the lipid binding 
glycosaminoglycan (GAG) chains (Figure 6) [42–44]. The band with size of 220 kDa 
corresponds to biglycan [45]. 
Figure 6 Effect of GKA on TGF-β mediated 35S-SO4 incorporation into proteoglycans 
by endothelial cells. Cells treated with TGF-β (2 ng/ml) +/−GKA (RO28-1675) 1-10 μM for 
24 h (checkered column) and SB431542 (3 μM)(horizontal stripes column) was used as TβR1 
antagonist. Media containing secreted proteoglycans was spotted on chromatography paper 
and CPC precipitated to assess radiolabel incorporation into proteoglycans. Results are mean 
± SEM of data normalised to control from three experiments in triplicate, ##p < 0.01 versus 
control and **p < 0.01 versus TGF-β using 1-way ANOVA. 
Effect of GKA on TGF-β mediated Smad2C phosphorylation in BAEC 
The canonical TGF-β signalling pathway leads to the rapid generation of pSmad2C. To test if 
GKA had any effects on upstream TGF-β signalling, BAEC were treated with TGF-β (2 
ng/ml) for 5 min in the presence of GKA (RO28-1675) (1-10 μM). We observed no effect of 
GKA on TGF-β stimulated pSmad2 levels (Figure 7). These data indicate that RO28-1657, 
which blocks glucose dependent Smad signalling does not directly block TGF-β activated 
Smad signalling in BAECs. 
Figure 7 Effects of GKA (RO28-1675) on TGF-β mediated Smad2C phosphorylation in 
endothelial cells. A. Western blot of whole cell lysates from BAECS treated with TGF-β (2 
ng/ml) for 5 min in the presence and absence of GKA (RO28-1675) (1-10 μM). SB431542 (3 
μM) was used as a positive control. Cell lysates were resolved on SDS-PAGE and transferred 
onto a PVDF membrane. This membrane was probed with anti-phosphoSmad(Ser465/467) 
Also reprobed for anti-Smad2 and anti-GAPDH. Chemiluminescence was used to detect the 
proteins of interest. B. Histogram is a densitometric quantitation of 3 Western blots. 
Direct actions of GKAs on vascular reactivity 
To further explore the effects of GKAs on endothelial and vascular smooth muscle cells, we 
investigated the direct effects of RO28-1675 in an established assay of vascular tone [33]. 
Arterioles, maximum lumen diameter 166.0 + 5.6 μm, displayed approximately 50% 
constriction once equilibrated to a lumen pressure of 70 mmHg at 34°C, dilated maximally in 
response to acetylcholine (99.3 ± 1.7% at 10 μM) and contracted significantly in the presence 
of phenylephrine (28.1 ± 1.1% 10 μM). In the presence of the glucokinase activator RO28-
1657 arterioles dilated to 66.7 ± 6.5%, at a concentration of 10 mM (P = 0.025, ANOVA, df7, 
40). There were no changes in diameter of arterioles treated with the DMSO vehicle. The 
modest dilation associated with acute RO28-1675 treatment did not alter the contractile 
sensitivity or maximum response to phenylephrine however it may possibly have increased 
the sensitivity to acetylcholine mediated dilatation (Figure 8). 
Figure 8 Changes in pressurised arteriole diameter as responses to increasing 
concentrations of GKA (RO28-1675). This figure shows the changes in pressurised arteriole 
diameter (myogenic tone) , expressed as a percentage of the maximum diameter (166 ± 6 μm) 
measured in 0 mM Ca
2+
/2 mM EGTA buffer. Results are the mean ± SEM from 6 
experiments. The upper panel shows the pressurised arteriole diameter responses to 
increasing concentrations of RO28-1675 or vehicle (DMSO). The * indicates a significant 
difference (ANOVA, p < 0.05, n = 6) between the RO28-1675 and vehicle treated arterioles. 
Centre panel, represents the dilatation in response to increasing concentrations of 
acetylcholine, alone and in the presence of 10 μM RO28-1675. Despite the greater baseline 
diameter in the presence of 10 μM RO28-1675, the response to acetylcholine was not 
different. Similarly the lower panel shows the constrictor response to the adrenoceptor 
agonist phenylephrine, was not different in the presence of 10 μM RO28-1675. 
Discussion 
We have evaluated the direct vascular effects of several GKAs. We established an islet cell 
assay that showed GKAs stimulated glucose utilisation and in the same assay in vascular 
endothelial cells, the drugs had no effect on glucose utilisation but TGF-β (which activates 
cellular metabolism) used as a positive control did stimulate glucose utilisation. We showed 
that high glucose in the media stimulated carboxy terminal phosphorylation of the pro-
fibrotic transcription factor Smad2 leading to the formation of pSmad2C in a parabolic 
response for time and concentration. This indicates glucose-mediated regulation of the TGF-β 
signalling pathway including the activation of TGF-β Type I receptor (TβRI/ALK V). 
Utilising the optimum stimulatory conditions for high glucose and pSmad2C formation, we 
showed that the GKA, RO-28-1675, rather than activating pSmad2C formation, actually 
inhibited high glucose stimulated pSmad2C formation in a concentration dependent manner 
with a half maximally inhibitory concentration of approximately 1 μM. TGF-β stimulation of 
the synthesis of the lipid-binding proteoglycan, biglycan, and the elongation of the GAG 
chains on biglycan represents one component of an in vitro model of atherogenesis because 
increased GAG chains have enhanced signalling for atherogenic lipoproteins; in this model, 
RO-128-1675 had no effects on TGF-β stimulated biglycan synthesis even at the highest 
concentration tested (10 μM) so we would conclude that GKAs are silent in this assay in 
contrast for example to glitazones which are anti-atherogenic [46]. 
RO128-1675 used as a model GKA, did not affect TGF-β stimulated pSmad2C formation 
indicating no inhibition of TGF-β signalling. We examined the effect of RO-128-1675 on 
tone of an isolated blood vessel. The GKA slightly relaxed the tissue under resting conditions 
and this response was lost as the vessel was maximally relaxed with acetylcholine or 
maximally contracted with phenylephrine. These data demonstrate that a model GKA drug 
does not have deleterious direct vascular actions in a range of cellular and tissue assays and 
hence that to the extent that these results can be extrapolated, if reflected in vivo, drugs 
activating GK will not have direct vascular actions which compromise any favourable actions 
resulting from the glucose lowering action of these drugs. This study clearly indicates that 
GKAs have no effect on glucose metabolism and atherogenic properties of vascular 
endothelial cells. 
Role of GKs in glucose homeostasis 
Glycaemia is mainly controlled by the glucose mediated release of insulin from the beta cells 
in the pancreas. The process of entry of glucose across the cell membrane is controlled by 
hexokinases (HKs) and glucose transporters [19, 20]. HK catalyses the initial step of glucose 
metabolism which is responsible for the conversion of glucose to glucose-6-phosphate (G-6-
P) creating a large inward gradient for the entry of glucose to cells via glucose transporters 
[15]. HK IV, also referred to as glucokinase (GK) is a 50 kDa protein with low affinity and 
high capacity for glucose and at a physiological concentrations it is not inhibited by its 
product (G-6-P) [15, 16]. GK has so far been found in the liver, pancreatic beta cells, brain 
(hypothalamus) and gut and it acts as a “glucose sensor” [15, 16]. GK plays an important role 
in pancreatic beta cell insulin secretion [47]. Studies on the importance of GK in insulin 
secretion, including gain-of-function and loss-of-function studies have shown that other HKI-
III isoforms have the ability to compensate for the loss of GK; in pancreatic GK knockout 
mice insulin release was still occurring in the absence of the GK enzyme [16, 48]. Also, liver 
HK knockout mice showed that glucose homeostasis was still maintained [16]. In the absence 
of GK enzyme in the pancreas and the liver, other HKs can take over the action of GK [16, 
48]. 
Hyperglycaemia and the complications of diabetes 
The hyperglycaemia of diabetes has deleterious effects on the microvascular and on balance 
negative effects on the microvasculature. Therapeutically lowering blood glucose levels can 
have beneficial effects on microvascular but the results are less clear for the 
macrovasculature. GKAs are a class of drugs which stimulate the uptake of glucose into cells. 
In the setting of diabetes this is most relevant in islet and liver cells. In islet cells, the 
stimulation of glucose uptake leads to enhanced insulin secretion and an overall 
hypoglycaemic effect being the mode of action of these drugs in Type 2 diabetes. However, if 
glucose causes damage to vascular cells then the stimulation of glucose uptake by GKAs 
might be expected to increase the glucose toxicity and oppose any action resulting from a 
reduction in glycaemia. 
Thus, GKAs might have deleterious actions due directly to their target being present in 
vascular endothelial cells and their mode of action increasing the effect of glucose with 
resulting deleterious effects. Additionally, many drugs have pleiotropic actions, often toxic 
actions unrelated to the prime mechanism of action of the index drug so we conducted 
experiments which evaluated the vascular actions of GKAs based on both of these scenarios. 
We established an assay that could demonstrate the action of a GKA to stimulate glucose 
uptake and utilisation in an islet cell line. Using the same experimental model we found that a 
GKA had no effect on glucose uptake and utilisation by vascular endothelial cells. These 
experiments exclude the possibility that GKAs might cause vascular toxicity by a mechanism 
which is inherent in their anti-hyperglycemic action in Type 2 diabetes. We then investigated 
the direct actions of GKAs on vascular cells and on intact blood vessels. 
Hypoglycaemic actions of GKAs 
GKA (RO28-1675) and Compound A are two members of anti-hyperglycemic GKA family 
of pre-clinical therapeutic agents. They act by increasing the activity of glucose-
phosphorylating enzyme GK in pancreatic beta cells leading to increased glucose uptake and 
insulin production and secretion [10]. We have confirmed the known mechanism of action of 
GKAs on rat MIN6 pancreatic beta cells expressing GK enzyme and found that GKAs 
(RO28-1675) and Compound A both appreciably increased the cellular utilization of glucose 
by MIN6 cells. Thus, GKAs stimulated GK enzyme in the MIN6 cells and caused an increase 
in the rate of glucose consumption. The presence and expression of glucokinase isoforms in 
vascular cells and tissues has not been extensively studied. Our assay of increased glucose 
utilisation assessed by depletion of glucose from the culture media over several hours is 
essentially a functional assay for the presence of a target in vascular cells which is stimulated 
by GKA drugs. That we found no effect of the GKA on glucose uptake in vascular 
endothelial cells indicates that a GKA sensitive isoform is not present in these cells or at least 
is not present at a level that could increase the exposure of cells to glucose. It is not unusual 
for therapeutic targets to be present in non-target tissues however it has not always been 
investigated. In the case of thiazolidinediones there was conflicting evidence as to the level 
and importance of the expression of PPAR-α [49] and PPAR-γ [50] in vascular smooth 
muscle cells and hence the contribution that such targets may make to the vascular actions of 
these drugs [51]. Our data allows for a favourable understanding that GKAs do not intensify 
the deleterious actions of glucose on vascular endothelial cells. 
Fibrotic actions of glucose via Smad transcription factors – inhibition by 
GKAs 
Recent published data shows that exposure of fibroblasts and epithelial cells to elevated 
levels of glucose enhances the activation of transforming growth factor TGF-β Type I 
receptor (TβRI)/Smad3 signalling and mediates the development of cellular hypertrophy [37]. 
In concurrence with these finding, our data clearly shows that HG can induce Smad 
signalling in BAEC. Western blotting analysis for carboxy terminal phosphorylated Smad2, 
revealed that glucose induced Smad2C phosphorylation with parabolic responses for both 
time and concentration. The HG induced Smad activation via the TGF-β signalling pathway 
is also supported by other studies [37]. Smad3 activation was observed in these cells in 
presence of HG demonstrating that Smad phosphorylation results from activation of autocrine 
TGF-β signalling [52–54]. It is noteworthy that the pSmad2C response in endothelial cells 
peaked in the pathophysiological range for glucose in people with Type 2 diabetes. Although 
the response declined at high concentration and longer time points it would be a reasonable 
assumption that regularly and widely varying glucose levels throughout the day in person 
with Type 2 diabetes might be associated with fluctuating levels of phosphorylated Smad and 
Smads are well known to be associated with fibrotic states such as kidney disease. The 
significance of this data is that the outcome of TGF-β receptor signalling in vascular cells is 
associated with de novo synthesis of collagen and plasminogen activator inhibitor 1 (PAI-1) 
which are well known fibrotic and pro-coagulant characteristics of the diabetic milieu [55–
58]. This data provided the basis for our experiments to test if GKA could intensify a glucose 
dependent response such as Smad2C phosphorylation in endothelial cells. 
We showed that GKA (RO28-1675) caused concentration dependent inhibition of glucose 
stimulated Smad2C phosphorylation levels in endothelial cells. This effect is independent of 
any action HK because GKA does not affect the HK enzyme in endothelial cells. GKA has 
caused a pleiotropic action, on glucose dependent signalling unrelated to known mechanism 
of action, which can further be investigated. This may be a favourable pleiotropic action 
because the GKA agent decreased the phosphorylation of Smad2C a response which is 
clearly pro-fibrotic in many tissues [55, 58]. 
Direct effects of GKAs on vascular proteoglycan synthesis 
We have studied the effect of GKA on proteoglycan, specifically biglycan synthesis, which 
was used as a model for the initiation of atherosclerosis [42, 44, 59]. TGF-β is known to 
increase the length of GAG chains on proteoglycans in endothelial cells [39]. Our aim was to 
further characterise the TGF-β mediated proteoglycan synthesis specifically 
glycosaminoglycan elongation in presence of GKA (RO28-1675). Our results showed that 
TGF-β increased proteoglycan synthesis, specifically GAG elongation but the GKA had no 
effect on radiolabeled sulfate incorporation into proteoglycans and does not play a role in 
TGF-β mediated GAG elongation in BAECs. This is in contrast to a range of anti- 
hyperglycaemic agents which do inhibit growth factor stimulated proteoglycan synthesis but 
much of this data in in vascular smooth muscle as opposed to the endothelial cells employed 
in the current studies [60, 61]. 
Since GKA (RO28-1675) blocked glucose dependent Smad2 phosphorylation but not the 
direct effects of TGF-β on proteoglycan synthesis in BAEC we looked directly the effects of 
RO28-1675 on upstream TGF-β signalling in the BAECs. We investigated the effect of GKA 
(RO28-1675) on TGF-β mediated Smad2C phosphorylation in endothelial cells. RO28-1675 
had no effect on TGF-β mediated Smad2C phosphorylation even at the highest concentration 
tested which had shown effects in other assays. This data has demonstrated that RO28-1675 
has no effect on TGF-β signalling in endothelial cells. 
Conclusions 
In conclusion, the new and emerging class of anti-hyperglycemic agents, glucokinase 
activators, have been investigated for their actions on vascular endothelial cells and intact 
blood vessels. We have demonstrated that there is no effect of GKAs on glucose utilisation 
by endothelial cells. A GKA had an inhibitory effect on glucose stimulated Smad 
phosphorylation an effect that must be independent of glucose metabolism because GKAs do 
not affect glucose metabolism in endothelial cells. We demonstrated that glucose stimulated 
Smad phosphorylation in a time and concentration dependent manner and this response, 
which might underpin some of the vascular glucotoxicity, was surprisingly blocked by a 
GKA. 
This unexpected action of GKAs, if long lasting and occurring in vivo, a parameter which is 
unknown at this time, will tend to be beneficial in the context of the processes causing 
diabetes vascular complications. Overall, we observed no effects of GKAs which would 
compromise the use of this class of drug treating the hyperglycaemia of Type 2 diabetes and 
based on this work the ultimate clinical utility will depend upon their long term anti-
hyperglycaemic actions and the extent to which this translate into reduced cardiovascular 
disease. 
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